Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
Hydromorphone hydrochloride is a semi-synthetic opioid analgesic available as an injectable solution for intramuscular, intravenous, or subcutaneous administration. It is indicated for moderate to severe pain management in patients requiring opioid therapy. The drug works by binding to mu-opioid receptors in the central nervous system to reduce pain perception.
Recent approval in growth stage positions this as a strategic asset for Hikma; commercial team expansion likely as market penetration increases.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration
Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration
An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain
A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain
An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer
Worked on HYDROMORPHONE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on hydromorphone hydrochloride post-launch positions professionals in a growth-stage product with significant commercial opportunity in the pain management market, though competitive and regulatory pressures are high. Roles emphasize sales execution, market access, and compliance with opioid regulations rather than scientific innovation.